Why the study?
Whether discharge residual mitral regurgitation and mean mitral pressure gradient are associated with outcomes after PASCAL mitral valve transcatheter edge-to-edge repair remains unknown.
Does achieving discharge residual mitral regurgitation ≤1+ reduce 1-year mortality in patients undergoing PASCAL mitral valve transcatheter edge-to-edge repair?
Does achieving discharge residual mitral regurgitation ≤1+ reduce 1-year mortality in patients undergoing PASCAL mitral valve transcatheter edge-to-edge repair?
Achieving a residual mitral regurgitation of ≤1+ at discharge is associated with lower 1-year mortality following PASCAL transcatheter edge-to-edge repair, even if mean pressure gradients are modestly elevated.
BACKGROUND: Residual mitral regurgitation (rMR) ≤1+ has been associated with improved 1-year outcomes after mitral valve transcatheter edge-to-edge repair, regardless of the mean mitral pressure gradient (MPG). Prior evidence is limited to 30-day echocardiographic follow-up and patients treated with the MitraClip (Abbott Structural Heart). Whether rMR and MPG assessed at discharge are associated with outcomes after PASCAL mitral valve transcatheter edge-to-edge repair (Edwards Lifesciences) remains unknown. METHODS: REPAIR (Registry of Pascal for Mitral Regurgitation) is an investigator-initiated, multicenter registry including all consecutive patients treated with PASCAL mitral valve transcatheter edge-to-edge repair. Based on discharge echocardiography, patients were stratified into 4 groups: optimal (rMR ≤1+, MPG <5 mm Hg), MPG-suboptimal (rMR ≤1+, MPG ≥5 mm Hg), rMR-suboptimal (rMR ≥2+, MPG <5 mm Hg), and dual-suboptimal (rMR ≥2+, MPG ≥5 mm Hg). The primary end point was 1-year mortality. CONCLUSIONS: Discharge rMR ≤1+ is independently associated with lower 1-year mortality after PASCAL mitral valve transcatheter edge-to-edge repair. Although MPG was not independently associated, modestly elevated gradients may be acceptable when rMR ≤1+ is achieved, but should still warrant clinical attention. REGISTRATION: URL: https://www.drks.de; Unique identifier: DRKS00033959.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: